Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Martina S. Lutz"'
Autor:
Ilona Hagelstein, Laura Wessling, Alexander Rochwarger, Latifa Zekri, Boris Klimovich, Christian M. Tegeler, Gundram Jung, Christian M. Schürch, Helmut R. Salih, Martina S. Lutz
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background Breast cancer (BC) is the most common malignancy in women. Immunotherapy has revolutionized treatment options in many malignancies, and the introduction of immune checkpoint inhibition yielded beneficial results also in BC. Howeve
Externí odkaz:
https://doaj.org/article/4fe2b27d65564a37932f57ac8d6d6e06
Autor:
Sylwia A. Stefańczyk, Ilona Hagelstein, Martina S. Lutz, Stefanie Müller, Samuel J. Holzmayer, Grace Jarjour, Latifa Zekri, Jonas S. Heitmann, Helmut R. Salih, Melanie Märklin
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Acute myeloid leukemia (AML) remains a therapeutic challenge despite recent therapeutic advances. Although monoclonal antibodies (mAbs) engaging natural killer (NK) cells via antibody-dependent cellular cytotoxicity (ADCC) hold promise in ca
Externí odkaz:
https://doaj.org/article/d7bb9722631649bdb4aa52e985e69282
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Pancreatic cancer is a highly lethal disease with limited treatment options. Hence, there is a considerable medical need for novel treatment strategies. Monoclonal antibodies (mAbs) have significantly improved cancer therapy, primarily due to their a
Externí odkaz:
https://doaj.org/article/53bad62c2c5e41ed83ea58e6d30172d5
Autor:
Martina S. Lutz, Latifa Zekri, Laura Weßling, Susanne Berchtold, Jonas S. Heitmann, Ulrich M. Lauer, Gundram Jung, Helmut R. Salih
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
T cell-based immunotherapy has significantly improved treatment options for many malignancies. However, despite these and other therapeutic improvements over the last decades, gastrointestinal cancers, in particular pancreatic, hepatic and gastric ca
Externí odkaz:
https://doaj.org/article/a9c1d07ea6db491a89f09555d59e60dd
Autor:
Nadine Aschmoneit, Katharina Kocher, Martin Siegemund, Martina S. Lutz, Lennart Kühl, Oliver Seifert, Roland E. Kontermann
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Targeting costimulatory receptors of the tumor necrosis factor superfamily (TNFSF) to activate T-cells and promote anti-tumor T-cell function have emerged as a promising strategy in cancer immunotherapy. Previous studies have shown that combining two
Externí odkaz:
https://doaj.org/article/576ebae1bf8c4fda872afd57290e2490
Autor:
Susanne M. Rittig, Martina S. Lutz, Kim L. Clar, Yanjun Zhou, Korbinian N. Kropp, André Koch, Andreas D. Hartkopf, Martina Hinterleitner, Lars Zender, Helmut R. Salih, Stefanie Maurer, Clemens Hinterleitner
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
In conventional T cells, OX40 has been identified as a major costimulating receptor augmenting survival and clonal expansion of effector and memory T cell populations. In regulatory T cells, (Treg) OX40 signaling suppresses cellular activity and diff
Externí odkaz:
https://doaj.org/article/5e3be70851314d40a577ae226ae4ff65
Autor:
Ilona Hagelstein, Martina S. Lutz, Moritz Schmidt, Jonas S. Heitmann, Elke Malenke, Yanjun Zhou, Kim L. Clar, Hans-Georg Kopp, Gundram Jung, Helmut R. Salih, Melanie Märklin, Clemens Hinterleitner
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Soft tissue sarcoma (STS) constitutes a rare group of heterogeneous malignancies. Effective treatment options for most subtypes of STS are still limited. As a result, especially in metastatic disease, prognosis is still dismal. The ligands for the ac
Externí odkaz:
https://doaj.org/article/c983352f25e8461eb8b95d844f20a749
Autor:
Jonas S. Heitmann, Tatjana Bilich, Marius Horger, Helmut R. Salih, Hans-Georg Kopp, Oliver Borst, Stefanie Maurer, Melanie Henning, Bettina Weigelin, Rupert Handgretinger, Marco Seehawer, Elke Malenke, Sophia Scheuermann, Christian Seitz, Clemens Hinterleitner, Stephan Singer, Martina Hinterleitner, Falko Fend, Lars Zender, Juliane S. Walz, Sven Mattern, Jasmin Strähle, Martina S. Lutz
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications
Nature Communications
Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI, however, robust markers to predict therapy response are missing. Here we sh
Autor:
Ilona Hagelstein, Latifa Zekri, Boris Klimovich, Martina S. Lutz, Carsten Greve, Stefanie Müller, Melanie Märklin, Bastian Schmied, Gundram Jung, Helmut R. Salih
Publikováno v:
Cancer Research. 82:2863-2863
Antitumor antibodies like Rituximab and Trastuzumab activate the patient’s immune system to engage malignant cells. Despite the advances achieved by their introduction in cancer treatment, an urgent medical need remains to improve and optimize the
Autor:
Latifa Zekri, Martina S. Lutz, Ilona Hagelstein, Timo Manz, Monika Engel, Boris Klimovich, Nisha Prakash, Anna Chashchina, Sebastian Hörner, Stefanie Müller, Melanie Märklin, Martin Pflügler, Gundram Jung, Helmut R. Salih
Publikováno v:
Cancer Research. 82:2865-2865
Despite substantial improvements over the last decades, survival rates in metastatic gastrointestinal cancer are still far from satisfactory, with an accordingly high medical need for new treatment strategies. B7-H3 (CD276) is a member of the B7 immu